Mitokinin
Mitokinin is a San Francisco-based, pre-commercial biotechnology company founded in 2017 that developed neuroscience medicines for neurological and psychiatric disorders, and has been acquired by AbbVie to strengthen its neuroscience pipeline.
- Company typePrivate
- Founded2017
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mitokinin does
Mitokinin is a San Francisco-based biotechnology company founded in 2017 that operated as a pre-commercial, R&D-stage biopharmaceutical developer focused on discovering medicines for neurological and psychiatric disorders. The company was built around an academic-founder scientific platform, with Kevan Shokat as founder and Daniel De Roulet as founder and CEO, and was backed by Pfizer Venture Investments across both its 2017 seed round (led by Mission BioCapital) and a 2018 financing of $5,000,000. The company was small, with 11-50 employees, and at the time of acquisition had not commercialized any product; the source material explicitly notes that pricing was not applicable given the R&D stage.
Mitokinin has since been acquired by AbbVie, which exercised its exclusive right to acquire the company to strengthen its neuroscience pipeline. The acquisition is structured as a strategic option-to-acquire, indicating the deal was tied to pipeline progress rather than commercial revenue. Following the acquisition, Mitokinin no longer operates as an independent entity; its assets and program are now part of AbbVie, headquartered in North Chicago, Illinois, an organization of approximately 55,000 employees focused on discovering and delivering transformational medicines and products across multiple therapeutic areas including neuroscience.
The business model was a classic early-stage biotech R&D model: capital was raised from strategic and venture investors to fund preclinical research, with the exit realized through acquisition by a large pharmaceutical company. There were no disclosed products, no pricing model, no customers, and no independent marketing or distribution channels at the time of acquisition; future commercialization, if successful, would have been executed through AbbVie's commercial infrastructure.
Mitokinin firmographics
Firmographics- Name
- Mitokinin
- Website
- https://mitokinin.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Mitokinin is a San Francisco-based, pre-commercial biotechnology company founded in 2017 that developed neuroscience medicines for neurological and psychiatric disorders, and has been acquired by AbbVie to strengthen its neuroscience pipeline.
- Ownership category
- akta.pro rank
Mitokinin industry classification
Industry- Product category
- Biopharmaceutical R&D
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Mitokinin is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mitokinin business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Mitokinin product offering
Product offeringCore offering
Mitokinin is a pre-commercial biopharmaceutical R&D company developing innovative medicines for patients with neurological and psychiatric disorders. The company was acquired by AbbVie, which exercised its exclusive right to acquire Mitokinin to strengthen AbbVie's neuroscience pipeline.
Product overview
No product information available. Mitokinin has been acquired by AbbVie and this source page only contains a corporate acquisition announcement. The page does not provide details about Mitokinin's specific products, services, or technology offerings.
Differentiator
Problem solved
Functional benefit
Companies that use Mitokinin
Customer profileSegments1 record
Ideal customer profiles1 record
Mitokinin technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Mitokinin partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AbbViecoreMitokinin has been acquired by AbbVie. The acquisition strengthens AbbVie's neuroscience pipeline. AbbVie exercised exclusive right to acquire Mitokinin to advance innovative medicines for neurological and psychiatric disorders.
Scale indicators2 records
Recent moves5 records
Expansion highlights2 records
Mitokinin competitors and assessment
Company assessmentDirect peers
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegeneration and lysosomal/mitochondrial diseases targeting CNS. Direct peer based on shared neuroscience focus and mitochondrial-biology approach to neurological disease.
- Cerevel Therapeutics: Neuroscience-focused biotech acquired by AbbVie, making it the closest comparator as a CNS-focused company now operating inside the same parent organization as Mitokinin.
- Prevail Therapeutics: Gene therapy company focused on neurodegenerative diseases including Parkinson's (GBA1), acquired by Eli Lilly. Direct comparable as a CNS-focused biotech pursuing disease-modifying therapies for neurology indications.
- Sage Therapeutics: CNS-focused biopharma developing therapeutics for neurological and psychiatric disorders. Direct peer in CNS innovation pharma, now part of Biogen.
- Voyager Therapeutics: Gene therapy company developing AAV-based treatments for CNS disorders including Parkinson's disease and ALS. Direct peer in CNS disease-modifying therapeutics targeting similar patient populations.
- Karuna Therapeutics: CNS-focused biotech developing therapies for neurological and psychiatric disorders (schizophrenia, dementia), acquired by Bristol-Myers Squibb. Direct peer in CNS innovation pharma space with similar exit profile.
Emerging players
- Cortexyme: Clinical-stage company developing therapeutics targeting microbial pathogens in neurodegenerative disease. Emerging peer in the neurodegeneration space with adjacent CNS focus.
- Athira Pharma: Clinical-stage CNS biotech developing small molecules for neurodegenerative diseases including Alzheimer's and Parkinson's. Emerging peer targeting similar CNS indications with disease-modifying approaches.
- Praxis Precision Medicines: Clinical-stage CNS biotech developing therapies for neurological and psychiatric disorders including movement disorders. Emerging peer in CNS precision medicine with overlapping indication space.
- Neuraly: Clinical-stage biotech developing therapeutics for neurodegeneration with a focus on mitochondrial dysfunction pathways. Emerging peer with shared interest in mitochondrial mechanisms in CNS disease.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Mitokinin social profiles
Digital presenceMitokinin financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mitokinin leadership team
Management profileNumber of profiles
Profiles2 records
Mitokinin funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mitokinin M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mitokinin
What does Mitokinin do?
Mitokinin is a pre-commercial biopharmaceutical R&D company developing innovative medicines for patients with neurological and psychiatric disorders. The company was acquired by AbbVie, which exercised its exclusive right to acquire Mitokinin to strengthen AbbVie's neuroscience pipeline.
When was Mitokinin founded?
Mitokinin was founded in 2017. It employs 11 to 50 people.
Where is Mitokinin based?
Mitokinin is headquartered in San Francisco, United States, in the North America region.
Who are Mitokinin's main competitors?
Direct peers on record are Denali Therapeutics, Cerevel Therapeutics, Prevail Therapeutics, Sage Therapeutics, Voyager Therapeutics and Karuna Therapeutics. Emerging players are Cortexyme, Athira Pharma, Praxis Precision Medicines and Neuraly.
Does Mitokinin have an API?
No public API is recorded for Mitokinin.
What industry is Mitokinin in?
Mitokinin's product category is Biopharmaceutical R&D. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.